Validating laboratory tests


is afixed dose combination of an anti-inflammatory (ICS) and a bronchodilator (LABA) in a p MDI device.Vectura earns revenue from product supply in addition to royalties on in-market net sales and is eligible to receive up to €30.0 million in future sales milestones from Mundipharma.This product has been launched to date in approximately 35 countries in Europe and elsewhere.In the period, Vectura recorded royalties and device sales of £2.0 million (proforma in Europe, and the product has now been launched in Poland, Germany, Austria and Portugal with further roll-out continuing.



During the period, there was continued roll-out into Asia Pacific and Latin America and the first enrollment into Mundipharma’s Phase III asthma study in China.As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements.We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.In July, Novartis reported net sales of $190 million for the six-month period to 30 June 2017, an increase of 10% on a constant currency basis compared to the same period in the prior year (six months ended 30 June 2016: $178 million).

This growth was fuelled by the FLAME study positive results and the recent GOLD guideline changes, which recommended LABA/LAMA as a treatment option in the majority of symptomatic patients regardless of their exacerbation risk.

In July, Novartis reported net sales of $72 million for the six-month period to 30 June 2017 (six months ended 30 June 2016: $74 million).